Guardant Health (GH) Stock Forecast, Price Target & Predictions
GH Stock Forecast
Guardant Health stock forecast is as follows: an average price target of $57.27 (represents a 97.76% upside from GH’s last price of $28.96) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
GH Price Target
The average price target for Guardant Health (GH) is $57.27 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $125.00 to $36.00. This represents a potential 97.76% upside from GH's last price of $28.96.
GH Analyst Ratings
According to 17 Wall Street analysts, Guardant Health's rating consensus is 'Buy'. The analyst rating breakdown for GH stock is 0 'Strong Buy' (0.00%), 16 'Buy' (94.12%), 1 'Hold' (5.88%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Guardant Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 21, 2024 | Dan Leonard | UBS | $40.00 | $27.68 | 44.51% | 38.12% |
| Aug 08, 2024 | Bill Bonello | Craig-Hallum | $37.00 | $31.36 | 17.97% | 27.76% |
| Aug 08, 2024 | Tycho Peterson | Jefferies | $40.00 | $33.96 | 17.79% | 38.12% |
| Jul 29, 2024 | Mark Massaro | BTIG | $50.00 | $35.28 | 41.72% | 72.65% |
| Jun 28, 2024 | Subbu Nambi | Guggenheim | $36.00 | $28.88 | 24.65% | 24.31% |
| Jun 04, 2024 | Kyle Mikson | Canaccord Genuity | $38.00 | $27.41 | 38.64% | 31.22% |
| Jun 03, 2024 | Tycho Peterson | Jefferies | $32.00 | $27.10 | 18.08% | 10.50% |
| May 23, 2024 | Mark Massaro | BTIG | $45.00 | $22.51 | 99.91% | 55.39% |
| May 22, 2024 | Kyle Mikson | Canaccord Genuity | $30.00 | $23.01 | 30.38% | 3.59% |
| Apr 24, 2024 | Chase Knickerbocker | Craig-Hallum | $28.00 | $17.93 | 56.12% | -3.31% |
The latest Guardant Health stock forecast, released on Aug 21, 2024 by Dan Leonard from UBS, set a price target of $40.00, which represents a 44.51% increase from the stock price at the time of the forecast ($27.68), and a 38.12% increase from GH last price ($28.96).
Guardant Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 10 |
| Avg Price Target | - | $40.00 | $37.60 |
| Last Closing Price | $28.96 | $28.96 | $28.96 |
| Upside/Downside | -100.00% | 38.12% | 29.83% |
In the current month, the average price target of Guardant Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Guardant Health's last price of $28.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 21, 2024 | UBS | Buy | Buy | Hold |
| Aug 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 08, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 08, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Aug 08, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 29, 2024 | BTIG | Buy | Buy | Hold |
| Jul 29, 2024 | William Blair | Outperform | Outperform | Hold |
| Jun 28, 2024 | Stephens | Buy | Buy | Hold |
| Jun 28, 2024 | Jefferies | Underperform | Underperform | Hold |
| Jun 28, 2024 | Guggenheim | - | Buy | Upgrade |
Guardant Health's last stock rating was published by UBS on Aug 21, 2024. The company gave GH a "Buy" rating, the same as its previous rate.
Guardant Health Financial Forecast
Guardant Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $143.03M | $137.15M | $128.71M | $126.89M | $117.40M | $109.14M | $96.10M | $108.11M | $94.78M | $92.10M | $78.67M | $78.32M | $74.57M | $66.33M | $67.51M | $62.90M | $60.85M |
| Avg Forecast | $266.69M | $257.31M | $243.53M | $228.97M | $228.95M | $217.90M | $204.34M | $190.45M | $186.79M | $170.49M | $162.59M | $150.09M | $149.60M | $137.35M | $129.85M | $117.87M | $123.82M | $117.75M | $105.08M | $95.77M | $98.65M | $92.01M | $84.52M | $73.75M | $76.74M | $65.93M | $59.18M | $56.48M | $54.87M | $45.41M |
| High Forecast | $274.98M | $265.32M | $251.11M | $236.09M | $236.07M | $224.68M | $210.70M | $198.29M | $188.34M | $170.54M | $162.59M | $150.64M | $154.25M | $137.35M | $133.89M | $121.54M | $127.67M | $117.75M | $105.08M | $95.77M | $98.65M | $92.01M | $84.52M | $73.75M | $76.74M | $65.93M | $59.18M | $56.48M | $54.87M | $45.41M |
| Low Forecast | $261.13M | $251.95M | $238.46M | $224.20M | $224.18M | $213.36M | $200.09M | $185.95M | $185.11M | $170.45M | $162.59M | $149.54M | $146.48M | $137.35M | $127.14M | $115.42M | $121.24M | $117.75M | $105.08M | $95.77M | $98.65M | $92.01M | $84.52M | $73.75M | $76.74M | $65.93M | $59.18M | $56.48M | $54.87M | $45.41M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 14 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 15 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.06% | 1.09% | 1.02% | 1.00% | 1.04% | 1.00% | 1.10% | 1.03% | 1.09% | 1.07% | 1.02% | 1.13% | 1.12% | 1.20% | 1.15% | 1.34% |
Guardant Health's average Quarter revenue forecast for Dec 23 based on 10 analysts is $149.60M, with a low forecast of $146.48M, and a high forecast of $154.25M. GH's average Quarter revenue forecast represents a 4.59% increase compared to the company's last Quarter revenue of $143.03M (Sep 23).
Guardant Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 14 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 15 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-113.54M | $-119.62M | $-132.65M | $-138.69M | $-151.43M | $-219.56M | $-115.41M | $-84.17M | $-101.24M | $-91.22M | $-103.89M | $-84.14M | $-76.63M | $-48.90M | $-22.90M | $-19.73M | $-9.76M |
| Avg Forecast | $-201.19M | $-194.12M | $-183.72M | $-172.73M | $-172.72M | $-164.38M | $-154.16M | $-143.67M | $-140.91M | $-128.62M | $-122.65M | $-139.64M | $-112.86M | $-103.62M | $-97.96M | $-126.95M | $-113.52M | $-96.13M | $-85.79M | $-115.41M | $-80.54M | $-75.12M | $-69.00M | $-80.55M | $-62.65M | $-53.83M | $-48.32M | $-28.78M | $-44.80M | $-37.07M |
| High Forecast | $-197.00M | $-190.07M | $-179.89M | $-169.14M | $-169.12M | $-160.96M | $-150.94M | $-140.28M | $-139.65M | $-128.58M | $-122.65M | $-111.71M | $-110.51M | $-103.62M | $-95.92M | $-101.56M | $-90.81M | $-96.13M | $-85.79M | $-92.33M | $-80.54M | $-75.12M | $-69.00M | $-64.44M | $-62.65M | $-53.83M | $-48.32M | $-23.02M | $-44.80M | $-37.07M |
| Low Forecast | $-207.45M | $-200.16M | $-189.44M | $-178.11M | $-178.09M | $-169.50M | $-158.95M | $-149.59M | $-142.09M | $-128.65M | $-122.65M | $-167.57M | $-116.37M | $-103.62M | $-101.00M | $-152.34M | $-136.22M | $-96.13M | $-85.79M | $-138.49M | $-80.54M | $-75.12M | $-69.00M | $-96.65M | $-62.65M | $-53.83M | $-48.32M | $-34.53M | $-44.80M | $-37.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.22% | 1.04% | 1.22% | 1.58% | 2.56% | 1.00% | 1.05% | 1.35% | 1.32% | 1.29% | 1.34% | 1.42% | 1.01% | 0.80% | 0.44% | 0.26% |
undefined analysts predict GH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Guardant Health's previous annual EBITDA (undefined) of $NaN.
Guardant Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 14 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 15 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-86.10M | $-72.77M | $-133.53M | $-139.93M | $-161.99M | $-229.43M | $-123.23M | $-72.31M | $-107.53M | $-97.58M | $-109.66M | $-93.75M | $-77.67M | $-54.64M | $-27.73M | $-25.21M | $-12.79M |
| Avg Forecast | $-61.49M | $-80.17M | $-70.90M | $-76.81M | $-85.19M | $-95.20M | $-90.89M | $-94.17M | $-95.94M | $-89.87M | $-92.72M | $-149.11M | $-106.09M | $-119.05M | $-149.78M | $-135.55M | $-122.61M | $-156.81M | $-148.66M | $-123.23M | $-135.71M | $-108.14M | $-100.30M | $-85.02M | $-69.46M | $-47.18M | $-45.09M | $-34.84M | $-36.87M | $-46.13M |
| High Forecast | $-59.82M | $-78.00M | $-68.98M | $-74.73M | $-82.88M | $-92.63M | $-88.43M | $-76.00M | $-86.34M | $-87.44M | $-90.21M | $-119.28M | $-94.68M | $-115.83M | $-145.72M | $-108.44M | $-98.09M | $-156.81M | $-148.66M | $-98.58M | $-135.71M | $-108.14M | $-100.30M | $-68.01M | $-69.46M | $-47.18M | $-45.09M | $-27.87M | $-36.87M | $-46.13M |
| Low Forecast | $-63.98M | $-83.42M | $-73.76M | $-79.91M | $-88.63M | $-99.06M | $-94.56M | $-123.91M | $-105.53M | $-93.51M | $-96.47M | $-178.93M | $-115.21M | $-123.87M | $-155.84M | $-162.66M | $-147.13M | $-156.81M | $-148.66M | $-147.87M | $-135.71M | $-108.14M | $-100.30M | $-102.02M | $-69.46M | $-47.18M | $-45.09M | $-41.81M | $-36.87M | $-46.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.49% | 0.99% | 1.14% | 1.03% | 1.54% | 1.00% | 0.53% | 0.99% | 0.97% | 1.29% | 1.35% | 1.65% | 1.21% | 0.80% | 0.68% | 0.28% |
Guardant Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Guardant Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 14 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 15 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $105.11M | $112.56M | $116.57M | $119.31M | $121.49M | $117.28M | $105.70M | $99.87M | $100.28M | $96.09M | $102.27M | $100.79M | $91.39M | $62.20M | $44.90M | $41.15M | $35.24M |
| Avg Forecast | $245.01M | $236.40M | $223.74M | $210.36M | $210.34M | $200.19M | $187.73M | $174.97M | $171.61M | $156.63M | $149.37M | $127.90M | $137.44M | $126.19M | $119.29M | $116.27M | $113.75M | $108.13M | $96.49M | $87.94M | $90.59M | $84.49M | $77.61M | $67.72M | $70.47M | $60.54M | $54.34M | $56.41M | $50.39M | $41.70M |
| High Forecast | $252.63M | $243.76M | $230.70M | $216.91M | $216.88M | $206.42M | $193.57M | $182.17M | $173.04M | $156.68M | $149.37M | $153.47M | $141.72M | $126.19M | $123.01M | $139.52M | $117.29M | $108.13M | $96.49M | $87.94M | $90.59M | $84.49M | $77.61M | $67.72M | $70.47M | $60.54M | $54.34M | $67.70M | $50.39M | $41.70M |
| Low Forecast | $239.91M | $231.48M | $219.08M | $205.98M | $205.96M | $196.02M | $183.82M | $170.83M | $170.07M | $156.59M | $149.37M | $102.32M | $134.58M | $126.19M | $116.81M | $93.02M | $111.39M | $108.13M | $96.49M | $87.94M | $90.59M | $84.49M | $77.61M | $67.72M | $70.47M | $60.54M | $54.34M | $45.13M | $50.39M | $41.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.94% | 1.00% | 1.05% | 1.12% | 1.22% | 1.20% | 1.10% | 1.19% | 1.24% | 1.51% | 1.43% | 1.51% | 1.14% | 0.80% | 0.82% | 0.85% |
Guardant Health's average Quarter SG&A projection for Dec 23 is $137.44M, based on 10 Wall Street analysts, with a range of $134.58M to $141.72M. The forecast indicates a 30.76% rise compared to GH last annual SG&A of $105.11M (Sep 23).
Guardant Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 14 | 9 | 9 | 9 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 11 | 15 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.73 | $-0.67 | $-1.30 | $-1.36 | $-1.58 | $-2.25 | $-1.21 | $-0.71 | $-1.06 | $-0.96 | $-1.09 | $-0.94 | $-0.78 | $-0.57 | $-0.29 | $-0.27 | $-0.14 |
| Avg Forecast | $-0.50 | $-0.65 | $-0.58 | $-0.62 | $-0.69 | $-0.77 | $-0.74 | $-0.77 | $-0.78 | $-0.73 | $-0.75 | $-0.88 | $-0.86 | $-0.97 | $-1.22 | $-1.34 | $-1.40 | $-1.28 | $-1.21 | $-1.21 | $-1.11 | $-0.88 | $-0.82 | $-0.89 | $-0.57 | $-0.39 | $-0.37 | $-0.39 | $-0.30 | $-0.38 |
| High Forecast | $-0.49 | $-0.63 | $-0.56 | $-0.61 | $-0.67 | $-0.75 | $-0.72 | $-0.62 | $-0.70 | $-0.71 | $-0.73 | $-0.86 | $-0.77 | $-0.94 | $-1.18 | $-1.30 | $-1.36 | $-1.28 | $-1.21 | $-1.21 | $-1.11 | $-0.88 | $-0.82 | $-0.89 | $-0.57 | $-0.39 | $-0.37 | $-0.39 | $-0.30 | $-0.38 |
| Low Forecast | $-0.52 | $-0.68 | $-0.60 | $-0.65 | $-0.72 | $-0.81 | $-0.77 | $-1.01 | $-0.86 | $-0.76 | $-0.78 | $-0.91 | $-0.94 | $-1.01 | $-1.27 | $-1.39 | $-1.46 | $-1.28 | $-1.21 | $-1.21 | $-1.11 | $-0.88 | $-0.82 | $-0.89 | $-0.57 | $-0.39 | $-0.37 | $-0.39 | $-0.30 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.55% | 0.97% | 0.97% | 1.23% | 1.85% | 1.00% | 0.64% | 1.20% | 1.17% | 1.23% | 1.66% | 2.02% | 1.55% | 0.74% | 0.90% | 0.37% |
According to undefined Wall Street analysts, Guardant Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GH previous annual EPS of $NaN (undefined).
Guardant Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PSNL | Personalis | $3.59 | $7.75 | 115.88% | Hold |
| GH | Guardant Health | $28.96 | $57.27 | 97.76% | Buy |
| MYGN | Myriad Genetics | $15.22 | $29.00 | 90.54% | Hold |
| CRL | Charles River Laboratories | $187.50 | $303.60 | 61.92% | Buy |
| ILMN | Illumina | $130.74 | $202.44 | 54.84% | Buy |
| CSTL | Castle Biosciences | $27.90 | $40.50 | 45.16% | Buy |
| CDNA | CareDx | $21.56 | $29.75 | 37.99% | Buy |
| DHR | Danaher | $230.06 | $305.47 | 32.78% | Buy |
| TMO | Thermo Fisher Scientific | $501.29 | $642.48 | 28.17% | Buy |
| A | Agilent | $126.92 | $152.64 | 20.26% | Buy |
| TWST | Twist Bioscience | $41.43 | $42.40 | 2.34% | Buy |
| NTRA | Natera | $153.42 | $120.92 | -21.18% | Buy |